> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Corrigan-Curay on Detail on CDER Director’s Office
- URL: https://www.fdaweb.com/corrigan-curay-on-detail-on-cder-directors-office/
- Published: 2021-02-09T12:00:00.000Z
- Updated: 2026-09-14T16:45:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148625

CDER Office of Medical Policy (OMP) director **Jacqueline Corrigan-Curay** has accepted a detail to the Office of the Center Director as deputy director for operations, effective 2/14\. While acting in this position, Corrigan-Curay will continue in her role as OMP director.

Corrigan-Curay’s temporary move is due to workload increases related to the Covid-19 response, according to CDER acting director **Patrizia Cavazzoni**. “Jacqueline will work on certain high-priority Center or agency-level programs or initiatives, while also continuing to lead the GDUFA 3 reauthorization negotiations,” she says. “As OMP director since 2016, Jacqueline has led staff in implementing medical policy programs and strategic initiatives for real-world evidence, drug labeling, prescription drug promotion, clinical trial oversight, and innovative trial design. Jacqueline also serves as a member of CDER’s Executive Committee, where she helps identify strategic priorities for the center and gives input on budget, hiring, technology, and investments.”

Before joining CDER, Corrigan-Curay served at NIH’s National Heart, Lung, and Blood Institute (NHLBI) on an initiative to optimize NHLBI’s clinical trials. She also served as the director of the Office of Biotechnology Activities, in the Office of NIH Director, focusing on optimizing the responsible conduct of clinical trials and laboratory research.

Corrigan-Curay has a law degree from Harvard Law School, and a medical degree from University of Maryland School of Medicine.